Epigenetic Clock Development Corporation
- Assets
- $1.2m
- Revenue
- $3.6m
- Investments
- $0.0
- Employees
- 6
- Location
- Torrance, CA
- Founding
- Data as of
- 12/2022
- EIN
- 85-1457272
Organization Overview
Epigenetic Clock Development Corporation is located in Torrance, CA. According to its NTEE Classification (H05) the organization is classified as: Research Institutes & Public Policy Analysis, under the broad grouping of Medical Research and related organizations. As of 12/2022, Epigenetic Clock Development Corporation employed 6 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Epigenetic Clock Development Corporation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Epigenetic Clock Development Corporation generated $3.6m in total revenue. All expenses for the organization totaled $3.4m during the year ending 12/2022.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE EPIGENETIC CLOCK DEVELOPMENT FOUNDATION ("CLOCK FOUNDATION") WAS FORMED TO ENABLE RIGOROUS MEDICAL RESEARCH ON AGING AND LONGEVITY. OUR RESEARCH MAINLY INVOLVES USE AND DEVELOPMENT OF NEW AGING BIOMARKERS KNOWN AS EPIGENETIC CLOCKS FOR TESTING THE EFFECTIVENESS OF LONGEVITY TREATMENTS WITHIN PRECLINICAL AND CLINICAL STUDIES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
INTERNAL RESEARCH PROGRAM: HIRING OF ADDITIONAL CLOCK FOUNDATION TEAM MEMBERS WE HIRED AN ADDITIONAL PHD BIOSTATISTICIAN, ALONG WITH ADDITIONAL PART-TIME OPERATIONAL, ADMINISTRATION, AND FINANCE STAFF. WE CONTINUED TO WORK CLOSELY WITH OUR SCIENTIFIC ADVISORY BOARD, ESPECIALLY ON THE DEVELOPMENT OF RIGOROUS APPROACHES FOR EPIGENETIC CLOCK TESTING. EXCLUSIVE UCLA IP LICENSE COMPLETED AN EXCLUSIVE LICENSE TO THE HORVATH IP PORTFOLIO WAS OBTAINED IN JUNE 2021. NO ADDITIONAL SUBLICENSES OR OUTLICENSING AGREEMENTS HAVE BEEN ENTERED INTO, ALTHOUGH WE ENTERED INTO SEVERAL RESEARCH COLLABORATION AGREEMENTS WITH GROUPS THIS YEAR.
OTHER PROGRAM SERVICES
EXTERNAL RESEARCH COLLABORATIONS: MANY INTERVENTIONAL STUDIES COMPLETED ONE OF THE MOST SIGNIFICANT PROMISES OF EPIGENETIC CLOCKS IS TO ACT AS A RELIABLE BIOMARKER TO EVALUATE PUTATIVE LONGEVITY TREATMENTS. WE CONDUCTED MANY NEW INTERVENTIONAL STUDIES, FOR CLINICAL TRIALS AND ALSO PRECLINICAL STUDIES, SOME WITH EXCITING EFFECTS AND OTHERS WITH MEDIOCRE OR NEGATIVE RESULTS. THIS INCLUDES STUDIES ON PLASMAPHARESIS, YOUNG PLASMA TREATMENT, STEM CELL EXOSOMES, UMBILICAL CORD PLASMA, AND A SENOLYTIC GENE THERAPY. MECHANISMS OF AGING STUDIES ONGOING ANOTHER KEY APPLICATION OF EPIGENETIC CLOCKS IS TO HELP ENABLE MECHANISTIC STUDIES, INCLUDING THE LINK OF EPIGENETIC AGING TO OTHER AGING HALLMARKS. EXCITING MECHANISTIC STUDIES THIS PAST YEAR INCLUDED ONES ON ERCC1 PROGERIA MODELS, BONE MARROW TRANSPLANTS, AND PROGERIA CELL LINES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Robert Brooke Executive Di | OfficerTrustee | 30 | $120,000 |
Stefan Horvath Director, Ch | Trustee | 40 | $106,042 |
Dean Prissman Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $0 |
| Total Program Service Revenue | $1,580,545 |
| Investment income | $116 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $3,593,807 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $226,042 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $134,155 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $21,585 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $36,318 |
| Fees for services: Accounting | $18,584 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $288,311 |
| Advertising and promotion | $23,078 |
| Office expenses | $660 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $60,918 |
| Travel | $5,120 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $49,792 |
| All other expenses | $45,490 |
| Total functional expenses | $3,391,084 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $638,291 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $510,227 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $9,955 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $35,250 |
| Total assets | $1,193,723 |
| Accounts payable and accrued expenses | $532,329 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $414 |
| Total liabilities | $532,743 |
| Net assets without donor restrictions | $660,980 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $1,193,723 |